

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 April 2025 (24.04.2025)



(10) International Publication Number
WO 2025/085553 A1

(51) International Patent Classification:

C07K 16/00 (2006.01) C07K 14/765 (2006.01)
A61K 39/395 (2006.01) C07K 16/18 (2006.01)

(21) International Application Number:

PCT/US2024/051639

(22) International Filing Date:

16 October 2024 (16.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/590,691 16 October 2023 (16.10.2023) US
63/702,533 02 October 2024 (02.10.2024) US

(71) Applicants: PARAGON THERAPEUTICS, INC.

[US/US]; 221 Crescent Street, Building 23, Suite 105,
Waltham, Massachusetts 02453 (US). VIRIDIAN THER-
APEUTICS, INC. [US/US]; 221 Crescent Street, Suite
103A, Waltham, Massachusetts 02453 (US).

(72) Inventors: LIU, Yuqi; 221 Crescent Street, Building 23,

Suite 105, Waltham, Massachusetts 02453 (US). OH, Jason
Z.; 221 Crescent Street, Building 23, Suite 105, Waltham,
Massachusetts 02453 (US). SHAHEEN, Hussam Hisham;

221 Crescent Street, Building 23, Suite 105, Waltham,
Massachusetts 02453 (US). VAZ, Rita L.; 221 Crescent
Street, Building 23, Suite 105, Waltham, Massachusetts
02453 (US). TSAI, Jordan; 221 Crescent Street, Suite
103A, Waltham, Massachusetts 02453 (US).

(74) Agent: KIM, Sang-A et al.; Proskauer Rose LLP, One In-
ternational Place, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: FCRN ANTAGONISTS WITH IMPROVED HALF-LIFE AND METHODS OF USE

ABD or albumin




FIGURE 1A

(57) Abstract: Described herein are Fc fusion molecules that bind FcRn (FcRn) with improved half-life and methods of use thereof.

[Continued on next page]

WO 2025/085553 A1

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))